MedTrace Logo

Validation of RDQ Questionnaire

NCT00291746 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2009-03-12

No results posted yet for this study

Summary

The primary objective of this study is to determine the accuracy of the Reflux Disease Questionnaire (RDQ) as a diagnostic test for gastroesophageal reflux disease. Symptom evaluation by the RDQ will be compared with other established approaches to the diagnosis of gastroesophageal reflux disease (GERD) in a primary care patient population with symptoms thought to be of upper gastrointestinal (GI) tract origin.

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

Esomeprazole

PROCEDURE

Bravo technique

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Nexium Medical Science Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-11-30

Countries

  • Canada
  • Denmark
  • Germany
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291746 on ClinicalTrials.gov